KKR to Acquire Disc Medicine
Ticker: IRON · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger
TL;DR
KKR is buying Disc Medicine, deal expected to close H1 2026.
AI Summary
Disc Medicine, Inc. announced on October 16, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of the global investment firm KKR. The transaction is expected to close in the first half of 2026, subject to customary closing conditions. This acquisition follows Disc Medicine's recent progress in its clinical programs.
Why It Matters
This acquisition by KKR signifies a significant financial event for Disc Medicine, potentially leading to delisting and a change in its operational structure.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the timeline for completion introduces some uncertainty.
Key Players & Entities
- Disc Medicine, Inc. (company) — Company being acquired
- KKR (company) — Acquiring entity
- October 16, 2025 (date) — Date of announcement
- first half of 2026 (date) — Expected closing period
FAQ
Who is acquiring Disc Medicine?
An affiliate of KKR is acquiring Disc Medicine.
When was the acquisition announced?
The acquisition was announced on October 16, 2025.
When is the acquisition expected to close?
The transaction is expected to close in the first half of 2026.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the former name of Disc Medicine?
Disc Medicine was formerly known as Gemini Therapeutics, Inc. /DE and FS Development Corp.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-17 08:43:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma
Filing Documents
- iron-20251016.htm (8-K) — 40KB
- 0001193125-25-242026.txt ( ) — 142KB
- iron-20251016.xsd (EX-101.SCH) — 24KB
- iron-20251016_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On October 16, 2025, Disc Medicine, Inc. (the "Company") announced that it received a Commissioner's National Priority Voucher ("CNPV") from the U.S. Food and Drug Administration ("FDA") for bitopertin in erythropoietic protoporphyria ("EPP"), including X-linked protoporphyria. As previously announced, the Company submitted a New Drug Application to the FDA for bitopertin for patients aged 12 years and older with EPP following the FDA's accelerated approval pathway in September 2025. The CNPV program, announced in June 2025, is designed to accelerate the development and review of certain drugs aligned with US national health priorities by offering the opportunity to reduce drug application review times to one to two months. Additionally, companies selected for the program will be issued a voucher entitling them to benefits including enhanced communications and rolling review to allow for shortened review time.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: October 17, 2025 By: /s/ John Quisel, J.D., Ph.D. John Quisel, J.D., Ph.D. Chief Executive Officer